Multigene genomic profiling has become the standard of care in the clinical risk-assessment and risk-stratification of ER-positive, HER2-negative breast cancer patients, with Oncotype DX® (ODX) emerging as the genomic profiling test with the most robust clinical data as well as the most support from the international community [1]. Here, ERBB2 is linked to breast cancer.